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We examined the possibility that the expression of adhesion molecules is regulated diﬀerently in cultured astrocytes from stroke-
prone spontaneously hypertensive rats (SHRSP/IZM) rats than in those from Wistar Kyoto rats (WKY/IZM) by tumor necrosis
factor-alpha (TNF-α) or hypoxia and reoxygenation (H/R) and the inhibitory eﬀects of apigenin. It was found that the expression
of vascular cell adhesion molecule-1 (VCAM-1) by TNF-α in astrocytes isolated from SHRSP/IZM was increased compared with
that in WKY/IZM. The expression of monocyte chemotactic protein-1 (MCP-1) mRNA induced by H/R in SHRSP/IZM astrocytes
was increased compared with that in normal oxygen concentrations. Apigenin strongly attenuated TNF-α-induced VCAM-1
mRNA and protein expression and suppressed the adhesion of U937 cells and SHRSP/IZM astrocytes. These results suggest that
the expression levels of adhesion molecules during H/R aﬀect disease outcome and can drive SHRSP/IZM to stroke. It is suggested
that apigenin regulates adhesion molecule expression in reactive astrocytes during ischemia.
1.Introduction
The onset of cerebral ischemia triggers a cascade of proin-
ﬂammatory molecular and cellular events. An important
role has been indicated for adhesion molecules such as
intercellular adhesion molecule-1 (ICAM-1) and p-selectin
in the recruitment of leukocytes in the postischemic cerebral
microvasculature. Blockade or genetic deletion of these
adhesion molecules has been demonstrated to reduce infarct
volume, edema, and/or mortality in diﬀerent animal models
of ischemic stroke [1]. Inﬂammatory cytokines such as
tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-
6) and several adhesion molecules are related to the presence
of early neurological deterioration and infarct volume [2,
3]. In particular, TNF-α and IL-6 are related to the risk
of recurrent ischemic stroke independently of conventional
risk markers [4, 5]. TNF-α is produced by microglial cells
and inﬁltrating macrophages following ischemic stroke and
may have neurotoxic and/or neuroprotective eﬀects [6].
Predictors of adverse stroke outcome include TNF-α,I C A M -
1, and IL-6 [7].
T h es t r o k e - p r o n es p o n t a n e o u s l yh y p e r t e n s i v er a t
(SHRSP/IZM) is characterized by cerebral hemorrhaging
and infarction and is extensively used for studying the eﬀects
o fd r u g so ns t r o k e[ 8]. In other words, SHRSP/IZM is
regarded as a useful genetic model of human hypertensive
stroke [9, 10]. Cerebral ischemia in SHRSP/IZM induces a
massive eﬄux of glutamate, causing delayed neuronal death
in the CA 1 region of the hippocampus, whereas Wister
Kyoto rats (WKY/IZM) lack these characteristics under
the same conditions [11]. The hippocampal neurons in
SHRSP/IZM are innately vulnerable to ischemia, but Ca2+
channel blockers prevent neuronal cell death in SHRSP [12].
SHRSP/IZM neurons are more vulnerable than WKY/IZM2 Stroke Research and Treatment
neurons during hypoxia and reoxygenation (H/R) [13–15].
The expression of monocyte chemoattractant protein-1
(MCP-1) was investigated in SHRSP/IZM rats with transient
ischemia in order to study the involvement of the inﬁltration
of monocytes from the blood in the mechanism of ischemia-
related neuronal death [16]. After ischemia and reperfusion,
MCP-1 mRNA was clearly induced in CA1, CA4, and
the molecular layer of the dentate gyrus. The majority of
MCP-1 expression occurred in astrocytes. These ﬁndings
suggest that astrocytes that express MCP-1 are related
to the pathological events of delayed neuronal death in
SHRSP/IZM [16]. It has been reported that the expression
of adhesion molecules in the astrocytes of SHRSP/IZM is
closely related to ischemia/reperfusion-induced neuronal
damage; however, the precise regulation of the expression of
adhesion molecules in SHRSP/IZM astrocytes has not been
elucidated.
Dietary ﬂavonoids act as antioxidants in human plasma
and other extracellular ﬂuids and protect low-density
lipoproteins (LDL) from oxidation [17]. The beneﬁcial
eﬀects of dietary ﬂavonoids can be explained by their antiox-
idative capacity and subsequent modulation of intercellular
redox maintenance, cell signaling, and gene expression [17].
Moreover, they reduce the cytokine-induced expression of
e-selection, ICAM-1, and vascular cell adhesion molecule-
1 (VCAM-1) in umbilical vein endothelial cells [18]. Fur-
thermore, in rat brain astrocytes, the activity and mRNA
of superoxide dismutase (SOD) were markedly increased
after incubation with catechin at a low concentration for
2d a y si nc u l t u r e[ 19]. On the other hand, resveratrol
signiﬁcantly attenuates the TNF-α induced expression of
nuclear factor-kappa B (NF-kappa B)-dependent inﬂamma-
tory markers, inducible nitric oxide synthase (iNOS), IL-
6, bone morphogenetic protein-2 (BMP-2), ICAM-1, and
VCAM-1 [20]. In addition, a recent study demonstrated
the protective eﬀects of resveratrol on enhanced hydrogen
peroxide toxicity in primary astrocytes [21]. Also, apigenin
eﬀectively reduces TNF-α induced ICAM-1 upregulation
in vivo through a mechanism that is unrelated to free
radical scavenging [22]. In this study, we compared the
drugs N-acetylcysteine (NAC), ebeselen, and pioglitazone
to determine the eﬀects of apigenin and resveratrol. It is
recognizedthatapigeninandresveratroldecreaseexpressions
of iNOS or VCAM-1 through inhibition of NF-kappa B
[20], while ebeselen, a therapeutic drug for stroke, attenuates
TNFα-induced ICAM-1 and VCAM-1 by inhibition of NF-
kappa B. Furthermore, pioglitazone, a therapeutic drug for
diabetes, reduces MCP-1 by stimulation of PPAR-γ [23], and
NAChasanantioxidant eﬀectandaninhibitory eﬀectofNF-
kappa B.
Astrocyte activation during H/R has been implicated
in the pathogenesis of SHRSP/IZM [24–26]. However,
the ischemic changes in astrocyte adhesion molecules of
SHRSP/IZM have not been clariﬁed. On the other hand,
TNF-α is produced by brain cells after various stimuli such
as ischemia. TNF-α induces the expression of adhesion
molecules for leukocytes in astrocytes. The expression of
adhesion molecules in the astrocytes by TNF-α is closely
related to ischemic stroke development in the acute setting.
Therefore, we were interested the expression of ICAM-1,
MCP-1, and VCAM-1 in the astrocytes of SHRSP/IZM rats
during stroke statuses such as H/R and TNF-α stimulation.
In this study, we investigated the expression of ICAM-1,
MCP-1, and VCAM-1 during H/R in cultured astrocytes
isolated from SHRSP/IZM. In addition, we were interested
in whether there are any modifying eﬀects on H/R-induced
expression in astrocytes of SHRSP/IZM rats caused by api-
genin, resveratrol, or other reagents such as pioglitazone. In
other words, we examined whether ﬂavonoids can modulate
gene expression.
2.MaterialsandMethods
2.1. Materials. Recombinant human TNF-α was purchased
from Roche Applied Science (Roche Applied Science,
Indianapolis, IN). Apigenin, resveratrol, ebselen, and N-
acetylcysteine (NAC) were obtained from Sigma-Aldrich,
Inc. (St. Louis, MO). Pioglitazone was obtained from Takeda
Pharmaceutical (Osaka, Japan).
2.2. Cell Culture. Primary astrocytes were prepared from
the cerebral cortices of fetal WKY/IZM and SHRSP/IZM
rats as described previously [27]. These primary astrocytes
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS,
Gibco Invitrogen, Grand Island, NY) at 37◦Ci naC O 2
incubator. The astrocytes were separated from other cells by
shaking the culture ﬂask at 220rpm for 5 hours. Cultures
with a homogeneous cell population (consisting of >95%
astrocytes as determined by glial ﬁbrillary acidic protein
staining) were used for the experiments [28]. Astrocytes
were inoculated on culture plates (Corning, Vernon, NY,
USA) and cultivated in DMEM containing 10% FBS until
conﬂuence was reached.
Human monocytic U937 cells were purchased from the
American Type Culture Collection (Rockville, MD, USA).
They were maintained in RPM-1640 medium supplemented
with 10% FBS. U937 cells were grown in suspension cultures
and subcultured 1 : 4 three times per week in 75-cm2 culture
ﬂasks.
2.3. Treatment of Cultures. The astrocytes were plated on
100mm cell culture dishes (Sumitomo Bakelite Co., LTD,
Tokyo, Japan) or 24-well plates (Corning) at an initial
density of 15 × 104 cells per cm2.T h ec e l l sw e r eg r o w n
at 37◦C ,u n d e r5 %C O 2, in a humidiﬁed atmosphere until
conﬂuent, which typically took 24–48 hours. They were then
incubated with or without TNF-α (10ng/mL) and diﬀerent
concentrations of apigenin or resveratrol (10, 30, or 50 μM)
for 0–24 hours.
2.4. Hypoxia and Reoxygenation. The astrocytes were incu-
bated in 1% O2, 94% N2, and 5% CO2 (hypoxia) for
24 hours. After hypoxic culture, they were maintained in
air (21% O2) and 5% CO2 (reoxygenation) for 3 hours
as previously described [13, 15]. Some groups underwent
further incubation (some groups before hypoxia and othersStroke Research and Treatment 3
Table 1: Sequences of primas for RT-PCR.
Gene Forward primer (5  → 3 ) Reverse primer (5  → 3 ) Amplicon (bp) Accession number
ICAM-1 TGTCAAACGGGAGATGAATGGT CGTCCCTGGTGATACTCCCA 71 NM 012967
MCP-1 GATGCAGTTAATGCCCCACTC CCAGCCGACTCATTGGGA 70 NM 031530
VCAM-1 GCTCGTACACCATCCGCAAG CGGTTTTCGATTCACACTCGT 66 NM 012889
after hypoxia) and received diﬀerent concentrations of
apigenin, resveratrol, ebselen, NAC, or pioglitazone.
2.5. Total RNA Extraction and cDNA. Total RNA was
extracted from cultured neurons using Trizol reagent (Gibco
Invitrogen). DNase I (Gibco, Invitrogen) was used to treat
RNA samples at room temperature for 15 minutes to remove
genomic DNA. DNase I was heated for 15 minutes at 65◦C
to inactivate it. First-strand cDNA synthesis was performed
with Superscript II (Gibco, Invitrogen).
2.6. RT-PCR. PCR was performed for adhesion molecule
gene expression. Primers were selected from Genbank and
designated using the primer design software Primer Express
(Applied Biosystems). Table 1 summarizes the primer sets
used. The reaction mixture (50μL) contained 200ng of the
cDNA sample; 1.25U of Ampli-Taq DNA polymerase; 1×
PCR reaction buﬀer; 200mM of each primer; 200mM of
dATP, dCTP, dGTP, and dTTP; and 1.5mM MgCl2 (Applied
Biosystems). The thermal cycling conditions were 5 minutes
at 95◦C, then 35 cycles of 94◦C for 30 seconds, 55◦Cf o r
30 seconds, and 72◦C for 30 seconds. After ampliﬁcation,
10μL of the reaction mixture were electrophoresed on a
2% NuSive : agarose (3 : 1) (FMC product, Rockland, ME)
gel and visualized with UV illumination after staining with
ethidium bromide. The amount of mRNA expressed was
measured relative to that per 18s ribosomal RNA. The
PCR conditions were conﬁrmed to be as described in the
abovementioned report and met the standard composition
and conditions used.
2.7.WesternBlotAnalysis. ThecellswerelysedinRIPAbuﬀer
(50mM Tris-HCl, pH 8.0, 150mM NaCl, 1% Nonidet P-40,
0.5% deoxycholic acid, 0.1% SDS), and the cell lysates (30–
50μg protein) were separated by SDS-PAGE and transferred
to polyvinylidene diﬂuoride membranes. The membranes
were incubated with antibody against the target protein
for 2 hours. After being washed twice, the membranes
were incubated with a horseradish peroxidase-conjugated
secondary antibody, and the protein levels were detected by
the enhanced chemiluminescence system (Invitrogen).
2.8. Astrocyte-U937 Cell Adhesion Assay. For the adhesion
assay, SHRSP/IZM astrocytes were resuspended in DMEM
medium with 10% FBS at the desired density and plated
in either 24-well or 96-well plates. Human monocyte-like
U937 cells (1 × 106 cells/mL) were added and incubated
with astrocytes at 37◦C for 3 hours. At the end of the
incubation, the wells were ﬁlled with culture medium and
aspirated three times to remove unbound U937 cells. The
adhesion of U937 cells to the astrocytes was measured using
quantitative monolayer adhesion assays, similar to those
previously described elsewhere [29]. Brieﬂy, the number of
bound U937 cells per square millimeter was determined by
direct microscopy. One randomly selected central ﬁeld and
four peripheral ﬁelds of the intact endothelial monolayers
were examined with an ocular grid using phase-contrast
microscopy (×200). The total number of bound U937 cells
was determined by a hemacytometer. The residual U937 cells
that were not removed from the empty wells by the washing
procedure typically represented −2% of the bound U937
cells in each experiment.
2.9. Statistical Analysis. Data are presented as means ±
SD. The signiﬁcance of diﬀerences was determined using
Fisher’s protected least signiﬁcant diﬀerence (PLSD) method
following an analysis of variance (ANOVA).
3. Results
3.1. A Comparison between the Gene Expression Levels of
Adhesion Molecules by TNF-α in Astrocytes Isolated from
WKY/IZM and SHRSP/IZM. We investigated the expres-
sion levels of ICAM-1, MCP-1, and VCAM-1 mRNA in
WKY/IZM and SHRSP/IZM astrocytes by exposure to TNF-
α (10ng/mL). As shown in Figure 1(a), the expression levels
of ICAM-1 and MCP-1 without TNF-α were the same in
WKY/IZM and SHRSP/IZM at 4 hours. On the other hand,
the expression levels of VCAM-1 and MCP-1 mRNA after
exposure to TNF-α in SHRSP/IZM were signiﬁcantly (P
< .05) higher than those in the astrocytes isolated from
WKY/IZM (Figure 1(b)).
3.2. The TNF-α-Induced VCAM-1 Protein Expression Levels
of WKY/IZM and SHRSP/IZM Astrocytes and It Inhibition
Eﬀect of Apigenin by Western Blotting. VCAM-1 activation
plays an important role in monocyte adhesion to astrocytes.
To conﬁrm the simultaneous protein expression of VCAM-
1w et r e a t e dt h ec e l l sw i t hT N F - α (10 ng/mL) and apigenin
(50μM) for 24 hours. The astrocytes isolated from SHRSP/
IZM were incubated with TNF-α (10ng/mL) and VCAM-
1 protein expression was studied. As shown in Figure 2,
the protein expression of VCAM-1 was enhanced by the
TNF-α treatments. Furthermore, the expression levels of
VCAM-1 protein after exposure to TNF-α in SHRSP/IZM
were signiﬁcantly (P < .05) higher than those in the
astrocytes isolated from WKY/IZM. On the other hand,
treatment with apigenin clearly reduced VCAM-1 protein
expression.4 Stroke Research and Treatment
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Figure 1: A comparison between the gene expression levels of ICAM-1, MCP-1, and VCAM-1 in astrocytes isolated from WKY/IZM and
SHRSP/IZM. The astrocytes isolated from WKY/IZM and SHRSP/IZM were washed with FBS-free DMEM, before TNF-α was added (a) or
not added (b) at 4 hours. Total cellular RNA was isolated from cultured astrocytes. The RNA was transcribed with reverse transcriptase and
ampliﬁed by RT-PCR. An 18s ribosomal RNA amplicon was used as an internal control for quantitation of the total amount of cDNA. The
bars represent the mean ± SD (n = 4). Asterisk (∗): P< . 05 compared with the WKY/IZM value. WKY: WKY/IZM; SHRSP: SHRSP/IZM.
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Figure 2: Eﬀects of TNF-α and apigenin on VCAM-1 pro-
tein expression levels in astrocytes isolated from WKY/IZM
and SHRSP/IZM. The astrocytes isolated from WKY/IZM and
SHRSP/IZM were incubated with TNF-α (10ng/mL) for 24 hours.
Levels of VCAM-1 protein were determined by Western blot
analysis.
3.3. The Eﬀects of Apigenin and Resveratrol on the TNF-
α-Induced Adhesion Molecule Gene Expression Levels of
SHRSP/IZM Astrocytes: Time Courses and Dose Response.
We further examined whether TNF-α (10ng/mL) was able
to induce the expression of ICAM-1, MCP-1, or VCAM-
1 mRNA in the astrocytes of SHRSP/IZM. Simultaneously,
we investigated the inhibitory eﬀects of 10μM of apigenin
or resveratrol on the TNF-α induced expression of these
molecules over a short period. TNF-α (10ng/mL) was
added to astrocytes for 0, 1, 2, or 4 hours to induce
the expression of ICAM-1, MCP-1, or VCAM-1 mRNA
(Figures 3(a), 3(b),a n d3(c)). As shown in Figure 3(a),
following the exposure to TNF-α, the ICAM-1 mRNA levels
increased time-dependently. The level of ICAM-1 mRNA
at 4 hours increased 1.35-fold compared with the 0 hour
control. Apigenin and resveratrol signiﬁcantly (P < .05)
inhibited TNF-α induced ICAM-1 mRNA expression to
its basal level. Also, the expression of MCP-1 increased
time-dependently after TNF-α exposure for 1, 2, or 4
hours (Figure 3(b)). The level of MCP-1 mRNA at 4 hours
was slightly increased to 1.10-fold of that of the 0 hours
control. Apigenin decreased (P < .01) the TNF-α-induced
expression of MCP-1, but resveratrol increased it at 1, 2,
and 4 hours. In addition, the expression levels of VCAM-
1 mRNA after exposure to TNF-α were strongly increased
to 2.01-fold (1 hour), 2.42-fold (2 hour), and 2.38-fold
(4 hour) compared with 0 hours control, respectively,
(Figure 3(c)). The level of VCAM-1 (2.38-fold) mRNA atStroke Research and Treatment 5
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Figure 3: The eﬀects of apigenin and resveratrol on the TNF-α-induced expression of ICAM-1, MCP-1, and VCAM-1 in astrocytes isolated
from SHRSP/IZM. Time course: the astrocytes isolated from SHRSP/IZM were washed with FBS-free DMEM, before (10μM) TNF-α and
apigenin or resveratrol were added. The astrocytes were cultured for 1, 2, or 4 hours. The ICAM-1(a), MCP-1 (b), and VCAM-1 (c) mRNA
measurements were carried out as described in Figure 1 and in the text. The bars represent the mean ± SD (n = 4). Asterisk (∗): P<. 05
compared with the expression level of TNF-α value at the same time. +Api; apigenin, +Res: resveratrol.
4 hours was higher than those of ICAM-1 (1.35-fold) and
MCP-1 (1.10-fold) after treatment with 10ng/mL TNF-α.
Apigenin strongly inhibited the augmented expression of
VCAM-1 mRNA. On the other hand, resveratrol enhanced
the augmented expression of VCAM-1 mRNA. Moreover,
we examined the dose-dependent eﬀects of apigenin and
resveratrol after exposure to TNF-α for 4 hours. As shown in
Figure 4(a), apigenin inhibited the dose-dependent expres-
sion of ICAM-1 and VCAM-1 mRNA induced by TNF-
α exposure at 10, 30, and 50μM but did not do the
same for MCP-1. On the other hand, resveratrol enhanced
the expression levels of MCP-1 mRNA induced by TNF-α
exposure at 10, 30, and 50μM. These adhesion molecule
gene expression patterns induced by TNF-α exposure were
dose-dependent over the course of the short examination
period. Concomitantly, we pointed out the inhibitory eﬀects
of apigenin on the gene expression patterns of adhesion
molecules.
3.4. A Comparison between the Gene Expression Levels of
Adhesion Molecules during Hypoxia and H/R in Astrocytes
Isolated from WKY/IZM and SHRSP/IZM. We investigated
the expression levels of ICAM-1, MCP-1, and VCAM-1
mRNA in WKY/IZM and SHRSP/IZM astrocytes during
normoxia, hypoxia, and H/R. As shown in Figure 5,i n
both WKY/IZM (Figure 5(a)) and SHRSP/IZM (Figure 5
(b)) hypoxia and H/R induced the expression of ICAM-
1, MCP-1, and VCAM-1 mRNA compared with normoxic
conditions. The expression levels of ICAM-1, MCP-1,
and VCAM-1 mRNA in the WKY/IZM astrocytes were
similar during hypoxia and H/R. On the other hand,
the expression of ICAM-1, MCP-1, and VCAM-1 of
SHRSP/IZM were higher than those of WKY/IZM during
hypoxia and H/R, respectively, and the expression levels of
ICAM-1, MCP-1, and VCAM-1 in the SHRSP/IZM were
higher than those in WKY/IZM during hypoxia and H/R,
respectively. Furthermore, the expression of MCP-1 mRNA
during H/R in the SHRSP/IZM astrocytes was markedly
increased.
3.5. The Eﬀects of Extending the Exposure Period of the Astro-
cytes to Apigenin or Resveratrol before and/or after Hypoxia.
Furthermore, we examined the eﬀects of extending the
exposure period of the astrocytes to apigenin or resveratrol
before hypoxia and/or after hypoxia on adhesion molecule
expression in SHRSP/IZM astrocytes. The astrocytes were
incubated for a longer period before hypoxia or after
hypoxia, with 10μM of apigenin or resveratrol. As shown in
Figure 6, the expression of adhesion molecules was inhibited
when the length of the exposure period to apigenin or6 Stroke Research and Treatment
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Figure 4:TheeﬀectsofapigeninandresveratrolonTNF-α-inducedexpressionofICAM-1,MCP-1,andVCAM-1inastrocytesisolatedfrom
SHRSP/IZM. Dose response: the astrocytes isolated from SHRSP/IZM were washed with FBS-free DMEM, replaced with DMEM containing
TNF-α (10ng/mL), and supplemented with 0, 10, 30, or 50μM of apigenin (a) or resveratrol (b). They were then incubated for 4 hours. The
ICAM-1, MCP-1, and VCAM-1 mRNA measurements were carried out as described in Figure 1 and in the text. The bars represent the mean
± SD (n = 4). Asterisk (∗): P<. 05 compared with the basal TNF-α value. TNF: TNF-α.
resveratrol was extended both before and after hypoxia.
However, the expression levels of the adhesion molecules
were enhanced when apigenin or resveratrol was added for
longer periods before or after hypoxia.
3.6. The Eﬀects of Apigenin, Resveratrol, Ebselen, NAC,
and Pioglitazone on H/R-Induced Adhesion Molecule Gene
Expression Levels in SHRSP/IZM Astrocytes. We investigated
the eﬀects of apigenin, resveratrol, ebselen, NAC, and piogli-
tazone on the H/R-induced adhesion molecule expression
levels of SHRSP/IZM astrocytes. All agents were added
before hypoxia and reoxygenation. As shown in Figure 7,
we indicated the H/R-induced expression levels of adhesion
molecules and the inhibitory eﬀects of apigenin, resvera-
trol, pioglitazone, NAC, and ebselen. Apigenin, resveratrol,
ebselen, NAC, and pioglitazone all reduced the expression
levels of MCP-1 and VCAM-1 mRNA. In particular, ebse-
len strongly decreased the H/R treated expression levels
of ICAM-1, MCP-1, and VCAM-1. The strength of the
inhibition of the expression of adhesion molecules was in the
following order: ebselen > NAC, apigenin = pioglitazone >
resveratrol.
3.7. The Inhibitory Eﬀects of Apigenin on U937 Cell Adhe-
sion in Cultured SHRSP/IZM Astrocytes. The adhesion of
U937 cells to astrocytes was measured using quantita-
tive monolayer adhesion assays [28]. Pretreatment of pri-
mary SHRSP/IZM astrocyte monolayers for 24 hours with
10ng/mL of TNF-α resulted in an increase in the adhesion
of U937 cells (Figure 8). Under similar conditions, 30μM
and 50μM of apigenin inhibited the adhesion of U937 cells.
In addition, pioglitazone strongly inhibited the adhesion of
U 9 3 7c e l l sa t1 0μM, 30μM, and 50μM. The inhibitory eﬀect
of pioglitazone was concentration dependent. Apigenin
inhibited the adhesion of U937 cells; however, the eﬀect of
apigenin was weak compared with that of pioglitazone.Stroke Research and Treatment 7
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Figure 5: A comparison between the gene expression levels of ICAM-1, MCP-1, and VCAM-1 in astrocytes isolated from WKY/IZM and
SHRSP/IZM during hypoxia and reoxygenation. The astrocytes isolated from WKY/IZM (a) or SHRSP/IZM (b) were incubated under
hypoxia (1% O2, 24 hour) or hypoxia + reoxygenation (21% O2, 3 hour) as previously described [13, 15]. The ICAM-1, MCP-1, and
VCAM-1 mRNA measurements were carried out as described in Figure 1 and in the text. The bars represent the mean ± SD (n = 4). Asterisk
(∗): P<. 05 compared with the normal condition values. Nor: normal condition, Hyp: Hypoxia, H/R: hypoxia and reoxygenation.
4. Discussion
The expression of adhesion molecules in astrocytes after
H/R has been implicated in the pathogenesis of SHRSP
[16]. In this study, we showed that the expression of
VCAM-1 mRNA and VCAM-1 protein induced by TNF-
α in astrocytes isolated from SHRSP/IZM is higher than
that induced in WKY/IZM. Furthermore, we examined the
H/R-induced expression levels of MCP-1 in SHRSP/IZM
astrocytes. Apigenin reduced the expression levels of ICAM-
1, MCP-1, and VCAM-1. In particular, treatment with
apigenin clearly reduced the VCAM-1 gene and VCAM-1
protein expression.
Leukocyte inﬁltration into the brain has been implicated
in the development of ischemic brain damage. A previous
study demonstrated that in vitro ischemia/reperfusion and
IL-1 β upregulate the expression of ICAM-1 in cultured
human endothelial cells and human fetal astrocytes [30].
Astrocytes respond to IL-1 β or in vitro ischemia/reperfusion
with a pronounced upregulation of IL-8 and MCP-1 mRNA
and by increased release of IL-8 and MCP-1 in cell culture
media.Astrocyteswerefoundtoreleasemuchhigherlevelsof
MCP-1 than endothelial cells under basal and ischemic con-
ditions. Furthermore, a previous report demonstrated that
RANTES (regulated on activation, normal T-cell expressed
and secreted), which is also known as CCL5, induces TNF-
α, which in turn stimulates the production of MCP-1. On
the other hand, a central role for astrocyte-derived MCP-
1 in leading the migration of monocytes and lymphocytes
acrosstheblood-brainbarrier(BBB)hasbeenindicated[31].
Consequently, astrocytes are considered as proinﬂammatory
cascade ampliﬁed and synthesize proinﬂammatory media-
tors [32]. In SHRSP/IZM, the expression levels of MCP-1 are
dramatically increased two days after ischemia-reperfusion.
It has been suggested that the onset of stroke is related to
the rapid increase in MCP-1 due to ischemia-reperfusion
in SHRSP [16]. We therefore demonstrated that the expres-
sion levels of VCAM-1 increase after TNF-α treatment in8 Stroke Research and Treatment
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Figure 6: The eﬀects of H/R on the expression levels of adhesion
molecules in astrocytes isolated from SHRSP and a comparison
between the inhibitory eﬀects of apigenin, resveratrol. The astro-
cytes isolated from SHRSP/IZM was incubated under hypoxia (1%
O2, 24 hour) or hypoxia + reoxygenation (21% O2, 3 hour) as
previouslydescribed[13,15].Theywereincubatedforanadditional
period either before hypoxia or after hypoxia with 50μMo f
apigenin or resveratrol. The ICAM-1, MCP-1, and VCAM-1 mRNA
measurements were carried out as described in Figure 1 and in
the text. The bars represent the mean ± SD (n = 4). Asterisk (∗):
P<. 05 compared with the normal condition values. Nor: normal
condition; Hyp: Hypoxia; H/R: hypoxia and reoxygenation.
astrocytes derived from SHRSP/IZM and showed that MCP-
1 expression increases during H/R. These ﬁndings support
the assertion that H/R induces the expression of MCP-
1, increases leukocytic inﬁltration, and promotes leukocyte
adhesion to brain cells in SHRSP/IZM.
Next, we examined the inhibitory eﬀects of the dietary
ﬂavonoids apigenin and resveratrol on the expression levels
of IVAM-1, VCAM-1, and MCP-1 after TNF-α treatment.
Apigenin inhibited the TNF-α induced expression levels of
ICAM-1, MCP-1, and VCAM-1. On the other hand, resver-
atrol reduced the expression levels of VCAM-1 but did not
reduce the expression levels of ICAM-1 or MCP-1. Further-
more, we demonstrated that apigenin as well as pioglitazone
attenuates the H/R-induced expression of MCP-1 mRNA.
A recent study showed that apigenin inhibits the secretion
of nitric oxide (NO) and prostaglandin E2 by suppressing
the expression of inducible nitric oxide synthase (NOS) and
cyclooxygenase-2 (COX-2) in murine microglia cell lines. In
addition, apigenin was also shown to protect neuronal cells
from injury after middle cerebral artery occlusion (MCAO).
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Figure 7: The eﬀects of H/R on the expression levels of adhesion
molecules in astrocytes isolated from SHRSP/IZM and a compar-
ison of the inhibitory eﬀects of apigenin and resveratrol, ebselen,
NAC, and pioglitazone. The astrocytes isolated from SHRSP/IZM
were incubated under hypoxia (1% O2, 24 hour) or hypoxia +
reoxygenation (21% O2, 3 hour) as previously described [13, 15].
They were incubated for an additional period either before or
after the hypoxia with 50μM of apigenin, resveratrol, ebselen,
NAC, or pioglitazone. The ICAM-1, MCP-1, and VCAM-1 mRNA
measurements were carried out as described in Figure 1 and in
the text. The bars represent the mean ± SD (n = 4). Asterisk (∗):
P<. 05 compared with the normal condition values. Nor: normal
conditions; Hyp: Hypoxia; H/R: hypoxia and reoxygenation.
Although it has been suggested that astrocyte activation
in SHRSP/IZM may be implicated in the pathogenesis of
stroke [16], the inhibitory eﬀects of ﬂavonoids includ-
ing apigenin on the expression patterns of SHRSP/IZM
astrocytes have not yet been elucidated. In this study, we
demonstrated that apigenin inhibits the expression of several
adhesion molecules in SHRSP/IZM. Ebselen (2-phenyl-1,2-
benzisoselenazol-3[2H]-one), a selenoorganic compound,
is eﬀective for treating acute ischemic stroke; however,
its eﬀect on SHRSP/IZM has not yet been elucidated.
We have previously demonstrated that ebselen is eﬀective
for the prevention and/or treatment of neurodegenerative
diseases associated with excessive apoptosis in patients with
stroke [15]. In this study, ebselen reduced the expression
levels of ICAM-1 and VCAM-1 mRNA. Other reports have
demonstrated that TNF-α-induced c-Jun N-terminal kinase
(JNK) activation is inhibited by ebselen in cultured human
umbilical vein endothelial cells (HUVECs). In addition, the
reduction of JNK by ebselen implied its usefulness for the
prevention of atherosclerosis, which is related to endothelialStroke Research and Treatment 9
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Figure 8: The inhibitory eﬀects of apigenin and pioglitazone
on U937 cell adhesion in astrocytes isolated from SHRSP. The
astrocytes isolated from SHRSP/IZM were cultured for 24 hours
with or without 10, 30, or 50μM of apigenin or pioglitazone and
were then challenged with TNF-α (10ng/mL). The U937 cells (1
× 106 cells/mL) were added and incubated with astrocytes at 37
◦C
for 3 hours. The adhesion of U937 cells to the astrocytes was
measured using quantitative monolayer adhesion assays, similar to
those previously described [28]. The inhibitory eﬀects of apigenin
are indicated (fold). The number of bound U937 cells per square
millimeter was determined by direct microscopy. The data are
means ± S.D (n = 6).
cell activation [33]. It has been suggested that the protective
eﬃcacy of ebselen against neurodegenerative diseases might
be implicated in the inhibitory eﬀects of adhesion molecule
expression, the inhibition of JNK [33], antioxidant eﬀects
[34], and the actions of glutathione mimics [35]. Also, we
have demonstrated that pioglitazone inhibits the expression
of MCP-1 mRNA. Pioglitazone is associated with a lower risk
of death, myocardial infarction, and stroke in patients with
diabetes [36]. Furthermore, pioglitazone shows protective
eﬀects against stroke in SHRSP/IZM, independently of
blood pressure [37] .T h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e d
receptor- (PPAR-) gamma agonist pioglitazone reduces
the incidence of stroke in patients with type 2 diabetes.
These actions of pioglitazone in astrocytes of SHRSP/IZM
may occur through stimulation of PPAR-gamma [23]. The
potent antioxidant NAC has been demonstrated to attenuate
cerebral ischemia-reperfusion injury in a rat model of
experimental stroke [38]. NAC reduced the expression of
TNF-α, IL-1 beta, and iNOS. Furthermore, a previous report
demonstrated that NAC, an antioxidant that inhibits NF-
kappa B activation, alters events in brain reperfusion injury.
NAC attenuates cerebral infarction by blocking activation
of NF-kappa B [39]. Furthermore, another report indi-
cated that apigenin inhibits p38 mitogen-activated protein
kinase (MAPK) JNK phosphorylation without aﬀecting the
activity of extracellular signal-regulated kinase (ERK) [40].
In addition, the inhibitory eﬀects of apigenin on ICAM-1
expression are mediated by the attenuation of the several
MAPK activities, c-fos and c-jun mRNA expression, and AP-
1 transcriptional activity and inhibit NF-kappa B [41, 42].
However, apigenin may decrease the expression levels of
adhesionmoleculessuchasMCP-1andVCAM-1byblocking
the activation of NF-kappa B in SHRSP/IZM during H/R
[38, 41].
5. Conclusions
In conclusion, we have demonstrated the TNF-α and
H/R-induced expression of adhesion molecules in primary
astrocytes of WKY/IZM and/or SHRSP/IZM. Furthermore,
apigenin, resveratrol, ebselen, pioglitazone, and NAC were
shown to modify adhesion molecule expression. Con-
comitantly, apigenin and pioglitazone strongly reduced the
adhesion of primary astrocytes isolated from SHRSP/IZM
and U937. These ﬁndings suggest that the expression of
adhesion molecules in astrocytes after H/R is implicated in
the pathogenesis of SHRSP/IZM. Moreover, it is suggested
that apigenin regulates the expression of adhesion molecules
in reactive astrocytes during ischemic statuses such as stroke.
Abbreviations
H/R: Hypoxia and reoxygenation
ICAM-1: Intercellular adhesion molecule-1
IL-6: Interleukin-6
MCP-1: Monocyte chemotactic protein-1
MCAO: Middle cerebral artery occlusion
NAC: N-acetylcysteine
SHRSP/IZM: Stroke-prone spontaneously hypertensive rats
TNF-α: Tumor necrosis factor-alpha
VCAM-1: Vascular cell adhesion molecule-1
WKY/IZM: Wistar Kyoto rats.
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